Detalhe da pesquisa
1.
Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience.
Blood
; 115(9): 1690-6, 2010 Mar 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-20018913
2.
Benefit from autologous stem cell transplantation in primary refractory myeloma? Different outcomes in progressive versus stable disease.
Haematologica
; 97(4): 616-21, 2012 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-22058223
3.
Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group.
Blood
; 112(8): 3130-4, 2008 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-18664623
4.
Minimal residual disease evaluation by flow cytometry is a complementary tool to cytogenetics for treatment decisions in acute myeloid leukaemia.
Leuk Res
; 40: 1-9, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26598032
5.
Stage IV and age over 45 years are the only prognostic factors of the International Prognostic Score for the outcome of advanced Hodgkin lymphoma in the Spanish Hodgkin Lymphoma Study Group series.
Leuk Lymphoma
; 53(5): 812-9, 2012 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-22185637
6.
Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results.
Blood
; 111(3): 1078-84, 2008 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-17975017